title: [A case of highly advanced ascending colon cancer with multiple bone and liver metastases and pleuritis carcinomatosa treated with pharmacokinetic modulating chemotherapy and low-dose CPT-11].
abstract: A 54 year-old male was admitted for highly advanced ascending colon cancer with multiple bone and liver metastases and pleuritis carcinomatosa. He was treated with pharmacokinetic modulating chemotherapy (PMC) and low-dose CPT-11. UFT (400 mg) was orally administered daily and a 2-hour infusion of l-leucovorin (250 mg/m2/day) with a continuous infusion of 5-FU (600 mg/m2/24 h) was given once a week on an outpatient basis. CPT-11 (80 mg/body/2 h) was administered every 2 weeks. Partial response was obtained in the liver for 6 months and in the primary lesion for 9 months. Significant decrease of pain from the multiple bone metastases was observed for 4 months without severe side effects, which led to an improvement in performance status and quality of life for the patient. He survived more than 11 months after initial treatment. The duration of his stay at home was 288 days, accounting for 83% of the treatment period. This case suggests the efficacy of home anticancer therapy with PMC and low-dose CPT-11 for highly advanced colon cancer in terms of QOL.
authors.affiliation: Dept. of Surgery, Japan Self Defense Force Hanshin Hospital.
authors.forename: Toshihiko
authors.initials: T
authors.lastname: Yagyu
authors.forename: Tsukasa
authors.initials: T
authors.lastname: Aihara
authors.forename: Michinori
authors.initials: M
authors.lastname: Murayama
authors.forename: Eisyu
authors.initials: E
authors.lastname: Nakamura
authors.forename: Hideto
authors.initials: H
authors.lastname: Nozaki
authors.forename: Masakuni
authors.initials: M
authors.lastname: Niida
authors.forename: Hiroki
authors.initials: H
authors.lastname: Yasuoka
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Nishimoto
authors.forename: Yoshinori
authors.initials: Y
authors.lastname: Watanabe
authors.forename: Shinichi
authors.initials: S
authors.lastname: Syouda
authors.forename: Toshihiko
authors.initials: T
authors.lastname: Kouno
authors.forename: Akinori
authors.initials: A
authors.lastname: Fukuhara
authors.forename: Katsuya
authors.initials: K
authors.lastname: Nakagawa
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000556:secondary; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000556:secondary*; D002166:Camptothecin / Q000008:administration & dosage* / Q000031:analogs & derivatives*; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004338:Drug Combinations; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D000077146:Irinotecan; D002955:Leucovorin / Q000008:administration & dosage; D008113:Liver Neoplasms / Q000556:secondary*; D008297:Male; D008875:Middle Aged; D010998:Pleurisy / Q000188:drug therapy* / Q000209:etiology; D011788:Quality of Life; D005641:Tegafur / Q000008:administration & dosage; D014498:Uracil / Q000008:administration & dosage
chemical_list: D004338:Drug Combinations; C096910:UFT(R) drug; D005641:Tegafur; D014498:Uracil; D000077146:Irinotecan; D002955:Leucovorin; D005472:Fluorouracil; D002166:Camptothecin